Ivospemin (SBP-101)

About Panbela Therapeutics

Panbela Therapeutics is a clinical-stage biotech focused on developing novel polyamine analog therapeutics for oncology, with a lead program in pancreatic cancer. The company's core achievement is advancing ivospemin (SBP-101) into a global Phase 3 trial (ASPIRE) for metastatic pancreatic ductal adenocarcinoma, following promising Phase 1b data. Its strategy centers on a capital-efficient, virtual model, targeting high-mortality cancers where polyamine pathway dysregulation is a key driver. Panbela aims to establish a new treatment paradigm by disrupting a fundamental metabolic pathway common across many aggressive tumors.

About Panbela Therapeutics

Panbela Therapeutics is a clinical-stage biotech focused on developing novel polyamine analog therapeutics for oncology, with a lead program in pancreatic cancer. The company's core achievement is advancing ivospemin (SBP-101) into a global Phase 3 trial (ASPIRE) for metastatic pancreatic ductal adenocarcinoma, following promising Phase 1b data. Its strategy centers on a capital-efficient, virtual model, targeting high-mortality cancers where polyamine pathway dysregulation is a key driver. Panbela aims to establish a new treatment paradigm by disrupting a fundamental metabolic pathway common across many aggressive tumors.

Therapeutic Areas